Archive: 2021

19

May2021

Aadi Bioscience Announces Preliminary Data for FYARRO™ in Patients with Solid Tumors Harboring TSC1 and TSC2 Alterations from a Multi-Institution Expanded Access Study to be Presented at ASCO 2021 Virtual Meeting

0  
LOS ANGELES, May 19, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience (“Aadi”), a privately-held biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, announces the release of an abstract selected for poster presentation at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting being ... Read More
May 19, 2021

17

May2021

Aerpio Pharmaceuticals and Aadi Bioscience Enter into a Definitive Merger Agreement

0  
Transaction to create Nasdaq-listed company focused on advancing Aadi Bioscience’s late-stage pipeline for genetically-defined cancers with alterations in mTOR pathway genes Concurrent $155 million PIPE financing is backed by leading life science investors led by Acuta Capital Partners and KVP Capital and including Avoro Capital Advisors; Avoro Ventures; Venrock Healthcare Capital ... Read More
May 17, 2021

11

Jan2021

Aadi Bioscience and EOC Pharma Announce License and Collaboration Agreement for ABI-009 (FYARRO™) in Greater China

0  
EOC Pharma acquires exclusive development and commercialization rights to ABI-009 in Greater China Aadi will receive an upfront payment, regulatory and sales milestone payments totaling up to $271M plus royalties Aadi Bioscience (Aadi), a biopharmaceutical company focusing on precision therapies for genomically defined cancers and EOC Pharma (EOC), a leading oncology specialty ... Read More
January 11, 2021